Instituto Finlay

Havana, Cuba

Instituto Finlay

Havana, Cuba
SEARCH FILTERS
Time filter
Source Type

Patent
Instituto Finlay | Date: 2014-01-29

The present invention relates to the field of immunology, specifically the branch of adjuvants and vaccines. The technical objective is to obtain adjuvants based on cochlear structures that are neither proteolipidic nor lipidic and that contain microbe-associated molecular patterns (MAMPs) and have the optional addition of antibiotics/chemotherapeutic agents with the aim of using them as vaccine adjuvants for the treatment and prevention of veterinary and human diseases. Additionally, these would be used as immunopotentiators in veterinary and human formulations. It is also a technical objective of this patent to utilize the said new cochlear structures with particular antigens added or liberated in vivo for the combined effect of immunopotentiation and antibiotics/chemotherapeutic agents in infectious diseases to obtain therapeutic vaccines for veterinary and human use in the pharmaceutical industry. The invention also relates to the method for obtaining sterile cochlear structures.


Arencibia-Arrebola D.F.,Instituto Finlay | Rosario-Fernandez L.A.,Institute Farmacia y Alimentos IFAL | Suarez-Fernandez Y.E.,Agricultural University of Havana
Revista Internacional de Andrologia | Year: 2011

Objective: This article has aimed to compare Balb/c, NMRI, OF-1 and C57BL/6/cenp mice as a biomodel in the assay of the sperm head basal cavity morphology, keeping in mind the frequency of anomalous forms of the basal head and cyclophosphamide-induced (CF) abnormalities. Materials and methods: Twenty animals/group/mice lines were used, administered for 35 days. A negative control group (not administered), two substance-vehicle controls and a positive control administered with 50. mg/kg FG intraperitoneally for five consecutive days were used. Results and discussion: The best experimental biomodel was with the Balb/c mice, with significant difference with the results obtained in the other lines, keeping in mind the spontaneous and induced values in the sperm concentration and frequency of anomalous epididymal sperms. This study will make it possible to use this mice species more efficiently in genotoxic and preclinical toxicology fertility evaluation of drugs, vaccines and other products. © 2011 Sociedad Española de Andrología.


Ledon T.,CSIC - National Center for Metallurgical Research | Ferran B.,CSIC - National Center for Metallurgical Research | Perez C.,CSIC - National Center for Metallurgical Research | Suzarte E.,CSIC - National Center for Metallurgical Research | And 4 more authors.
Microbes and Infection | Year: 2012

No commercially live vaccine against cholera caused by Vibrio cholerae O139 serogroup is available and it is currently needed. Virulent O139 strain CRC266 was genetically modified by firstly deleting multiple copies of the filamentous phage CTXφ, further tagging by insertion of the endoglucanase A coding gene from Clostridium thermocellum into the hemagglutinin/protease gene and finally deleting the mshA gene, just to improve the vaccine biosafety. One of the derived strains designated as TLP01 showed full attenuation and good colonizing capacity in the infant mouse cholera model, as well as highly immunogenic properties in the adult rabbit and rat models. Since TLP01 lacks MSHA fimbriae, it is refractory to infection with another filamentous phage VGJφ and therefore protected of acquiring CTXφ from a recombinant hybrid VGJφ/CTXφ. This strategy could reduce the possibilities of stable reversion to virulence out of the human gut. Furthermore, this vaccine strain was impaired to produce biofilms under certain culture conditions, which might have implications for the strain survival in natural settings contributing to vaccine biosafety as well. The above results has encouraged us to consider TLP01 as a live attenuated vaccine strain having an adequate performance in animal models, in terms of attenuation and immunogenicity, so that it fulfills the requirements to be evaluated in human volunteers. © 2012 Institut Pasteur.


Fabra M.J.,Universidad Politécnica de Ingeniería | Marquez E.,Institute Investigadores Para la Industria Alimentaria | Castro D.,Instituto Finlay | Chiralt A.,Universidad Politécnica de Ingeniería
Journal of Food Engineering | Year: 2011

Water sorption behaviour at 25 °C and the water content (x w)-glass transition temperature (T g)-water activity (a w) relationship was determined for noni pulp powder obtained by spray-drying with and without maltodextrin (DE 9-12), at three different MD/noni solid ratios of 1.17, 1.3 and 2.5, in order to know the effect of MD in the powder stability, preventing powder stickiness. The obtained isotherms were sigmoidal and the Guggenheim-Anderson-deBöer (GAB) model was fitted to the experimental data. The glass transition temperatures (T g) of the different noni powders and maltodextrin in DE 9-12 were obtained using differential scanning calorimetry (DSC). The equilibrium water content of noni samples containing maltodextrin at a given water activity was lower than that obtained for the maltodextrin-free noni powder. At 25 °C, the critical water content that ensures the glassy state of the noni pulp during storage increased from 0.047 to 0.06 g water/g product when the maltodextrin/noni ratio was greater than 1.3, while the critical water activity increased from 0.13 to nearly 0.5. © 2010 Elsevier Ltd. All rights reserved.


Meseguer V.,University Miguel Hernández | Alpizar Y.A.,Laboratory of Ion Channel Research | Luis E.,University Miguel Hernández | Tajada S.,University of Valladolid | And 18 more authors.
Nature Communications | Year: 2014

Gram-negative bacterial infections are accompanied by inflammation and somatic or visceral pain. These symptoms are generally attributed to sensitization of nociceptors by inflammatory mediators released by immune cells. Nociceptor sensitization during inflammation occurs through activation of the Toll-like receptor 4 (TLR4) signalling pathway by lipopolysaccharide (LPS), a toxic by-product of bacterial lysis. Here we show that LPS exerts fast, membrane delimited, excitatory actions via TRPA1, a transient receptor potential cation channel that is critical for transducing environmental irritant stimuli into nociceptor activity. Moreover, we find that pain and acute vascular reactions, including neurogenic inflammation (CGRP release) caused by LPS are primarily dependent on TRPA1 channel activation in nociceptive sensory neurons, and develop independently of TLR4 activation. The identification of TRPA1 as a molecular determinant of direct LPS effects on nociceptors offers new insights into the pathogenesis of pain and neurovascular responses during bacterial infections and opens novel avenues for their treatment. © 2014 Macmillan Publishers Limited. All rights reserved.


Batista-Duharte A.,University of Medical Sciences of Costa Rica | Lastre M.,Instituto Finlay | Perez O.,Instituto Finlay
Enfermedades Infecciosas y Microbiologia Clinica | Year: 2014

To achieve effective and safe vaccines for the prevention of not yet controlled or re-emergent infectious diseases, one of the more importance aspects is to have immunological adjuvants that allow inducing a protective immune response with an appropriate safety profile. Since 1926 the aluminium compounds have been used as adjuvants for human vaccines, and only in the last 10 years some new products have been registered. Although there an enormous quantity of proposed candidates, the toxicity is the main factor that has limited their introduction into the clinic. In this work the mechanism of action are updated, and the toxicity of the immunological adjuvants are revised, especially those that have obtained clinical approval or are close to getting it.© 2012 Elsevier Españna, S.L. Todos los derechos reservados.


Alba A.,Institute Medicina Tropical Pedro Kouri | Hernandez H.M.,Institute Medicina Tropical Pedro Kouri | Marcet R.,Institute Medicina Tropical Pedro Kouri | Vazquez A.A.,Institute Medicina Tropical Pedro Kouri | And 4 more authors.
International Journal for Parasitology | Year: 2015

Fasciolosis is a globally distributed snail-borne disease which requires economic consideration due to its enormous impact on veterinary medicine. During recent decades, this parasitosis has also shown increasing prevalence in human populations worldwide. The dissemination and successful transmission of fasciolosis ultimately depends on the existence of susceptible snails that act as intermediate hosts. Therefore, to accomplish effective control of this disease, surveillance and detection of the infected intermediate host would be essential. The screening of trematodes within snails using classical parasitological examination of the larvae can be unreliable (sensitivity and specificity vary depending on the time of infection and the experience of the observer) and relatively costly when using molecular biological methods during large-scale monitoring. Here we propose a novel monoclonal antibody-based immunoenzymatic assay to detect ongoing Fasciola hepatica infection in lymnaeid snails. Anti-. F. hepatica rediae mouse monoclonal antibodies were generated and used to develop a double monoclonal antibody-based ELISA for parasite detection. Fasciola hepatica-infected and uninfected laboratory-reared Galba cubensis and Pseudosuccinea columella were used for assessment of the developed ELISA. Experimentally infected snails were dissected and examined for parasite larvae as the "gold standard" method. Sensitivity results were 100% for both snail species, while specificity was 98% for G. cubensis and 100% for P. columella. No cross-reactivity was detected in lymnaeids infected with Trichobilharzia sp. or Cotylophoron sp. The ELISA enabled detection of the infection from day 8 p.i. in G. cubensis while in P. columella it was noted as early as day 4. To our knowledge no previous immunoassays have been reported to detect helminth-infected snails and the developed sandwich ELISA method is therefore suggested for infection status validation in natural populations of lymnaeid snails. © 2014 Australian Society for Parasitology Inc.


Patent
Instituto Finlay | Date: 2013-01-23

The invention relates to the field of vaccinal compositions for the effective or preventive treatment of vertically transmitted infections, especially malaria and preferably human malaria caused by Plasmodium falciparum. The technical aim of the invention is to use the tolerogens transferred, at an early stage, from the mother to the foetus/newborn and to formulate them with potent adjuvants that are inducers of Th1 and cytotoxic T-cell responses in order to use same in prophylactic or therapeutic vaccines against vertically transmitted infections, especially malaria. The use of said formulations at early ages via the parenteral route or via the mucosal route or both at the same time reverts the tolerance induced by the transfer of tolerogens, thereby inducing protective responses.


Patent
Instituto Finlay | Date: 2011-08-24

The invention is related to the field of vaccines. The technical objective is to obtain novel unitemporal therapeutic and prophylactic vaccines (single time vaccination strategy) using simultaneously one or more mucosal doses and one parenteral dose where the use of potent mucosal adjuvants are essential, preferable the Cochleate (AFCo1, Adjuvant Finlay Cochleate 1). The incorporation or co-administration by parenteral and mucosal routes of non-related PL antigens (heterologous), and/or the additional use of delivery systems like Aluminum, Chitosan or oil/water emulsions by parenteral application is also included in this invention. The induction of cellular immune responses than including systemic specific IgG and secretory specific IgA is obtained with at least two simultaneously doses. So, this unitemporal strategy is applicable to obtaining new unique or multiples vaccines (several mucosal vaccine antigens with the corresponding parenteral combine vaccine) in the pharmaceutical industry which permit to increase vaccine coverage and reduce the time-cost of vaccine campaigns.


The present invention has applications in the field of immunology, specifically in the sphere of adjuvants and vaccines. The invention aims at obtaining cochlear structures from vesicles found in the outer membranes of microorganisms, in order to employ them in the preparation of adjuvants and vaccines. The invention also discloses a method for obtaining cochlear structures.

Loading Instituto Finlay collaborators
Loading Instituto Finlay collaborators